Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 182.19 INR 1.29% Market Closed
Market Cap: 82.6B INR
Section:
 

Relative Value

The Relative Value of one MARKSANS stock under the Base Case scenario is 237.95 INR. Compared to the current market price of 182.19 INR, Marksans Pharma Ltd is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MARKSANS Relative Value
Base Case
237.95 INR
Undervaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3
P/S
P/S
Price to Sales
3
vs History
36
vs Industry
30
Median 3Y
3.3
Median 5Y
2.5
Industry
2.6
Forward
2.9
More Details
23.5
P/E
P/E
Price to Earnings
23.5
vs History
26
vs Industry
16
Median 3Y
22.9
Median 5Y
15
Industry
21.4
Forward
21.3
More Details
40.3
P/OCF
P/OCF
Price to OCF
40.3
vs History
23
vs Industry
9
Median 3Y
32.6
Median 5Y
21.5
Industry
16.4
More Details
3 149.8
P/FCFE
P/FCFE
Price to FCFE
3 149.8
vs History
9
vs Industry
0
Median 3Y
30.8
Median 5Y
27.8
Industry
22.8
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
52
vs Industry
16
Median 3Y
3.5
Median 5Y
3.1
Industry
2.2
More Details
2.9
EV/S
EV/S
Enterprise Value to Sales
2.9
vs History
38
vs Industry
30
Median 3Y
3.1
Median 5Y
2.2
Industry
2.9
Forward
2.7
More Details
5.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.1
vs History
38
vs Industry
29
Median 3Y
5.8
Median 5Y
4.3
Industry
5.5
More Details
15.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.5
vs History
26
vs Industry
19
Median 3Y
14.7
Median 5Y
9.6
Industry
13
Forward
14.5
More Details
18.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.9
vs History
26
vs Industry
20
Median 3Y
17.3
Median 5Y
11.2
Industry
16.5
Forward
19.3
More Details
38.5
EV/OCF
EV/OCF
Enterprise Value to OCF
38.5
vs History
25
vs Industry
9
Median 3Y
30.5
Median 5Y
18.7
Industry
15.6
More Details
227.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
227.7
vs History
28
vs Industry
2
Median 3Y
212.3
Median 5Y
35.1
Industry
18.7
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
53
vs Industry
15
Median 3Y
3.9
Median 5Y
3.2
Industry
1.9
More Details

Multiples Across Competitors

MARKSANS Competitors Multiples
Marksans Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Marksans Pharma Ltd
NSE:MARKSANS
82.6B INR 3 23.5 15.5 18.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.4 158.7
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.5 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average P/E: 24.2
23.5
15%
1.6
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average EV/EBITDA: 401.2
15.5
12%
1.3
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average EV/EBIT: 1 713.9
18.9
8%
2.4
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
MARKSANS intrinsic value, competitors valuation, and company profile.
DCF Valuation
MARKSANS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MARKSANS stock valuation using valuation multiples.
Wall Street Estimates
MARKSANS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MARKSANS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.